biostudies-literatureLeddy OU.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)NIAID NIH HHSNIEHS NIH HHSNCI NIH HHSNIGMS NIH HHSU.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)1196-1222https://www.ebi.ac.uk/biostudies/studies/S-EPMC12012165biostudies-literatureUnknown20(5)Vaccines and immunotherapies that target peptide-major histocompatibility complexes (peptide-MHCs) have the potential to address multiple unmet medical needs in cancer and infectious disease. Designing vaccines and immunotherapies to target peptide-MHCs requires accurate identification of target peptides in infected or cancerous cells or tissue, and may require absolute or relative quantification to identify abundant targets and measure changes in presentation under different treatment conditions. Internal standard parallel reaction monitoring (also known as 'SureQuant') can be used to validate and/or quantify MHC peptides previously identified by using untargeted methods such as data-dependent acquisition. SureQuant MHC has three main use cases: (i) conclusive confirmation of the identitiNature protocolsValidation and quantification of peptide antigens presented on MHCs using SureQuant.PMC120121651R35GM142900R35 GM142900U54 CA283114R01 AI022553P30 AI060354R01AI022553P42 ES027707U01 CA238720Kim DHBryson BDChoe EWhite FMCui YSpranger SStopfer LLeddy ORoerden MAhn RfalseValidation and quantification of peptide antigens presented on MHCs using SureQuant.Vaccines and immunotherapies that target peptide-major histocompatibility complexes (peptide-MHCs) have the potential to address multiple unmet medical needs in cancer and infectious disease. Designing vaccines and immunotherapies to target peptide-MHCs requires accurate identification of target peptides in infected or cancerous cells or tissue, and may require absolute or relative quantification to identify abundant targets and measure changes in presentation under different treatment conditions. Internal standard parallel reaction monitoring (also known as 'SureQuant') can be used to validate and/or quantify MHC peptides previously identified by using untargeted methods such as data-dependent acquisition. SureQuant MHC has three main use cases: (i) conclusive confirmation of the identiti2025-01-01T00:00:00Z2025 May2026-06-05T07:37:54.948Z2026-05-14T03:12:47.156ZS-EPMC120121653943869710.1038/s41596-024-01076-x